Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ET1402L1-ARTEMIS2
- Development stage
- Unknown
- Lead developer
- Eureka Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intratumoral, Intra-hepatic Artery
01
Overview
ET1402L1-ARTEMIS2 is an autologous chimeric antigen receptor T cell therapy (CAR-T) designed to target and kill tumor cells expressing the alpha-fetoprotein (AFP) peptide in complex with human leukocyte antigen HLA-A02, which is highly expressed in hepatocellular carcinoma (HCC).[1][3][5] The therapy employs the ARTEMIS2 receptor, engineered with a TCR-mimic antibody domain, enabling T cell recognition and destruction of AFP+ liver cancer cells.[1][3][7][9] It is developed primarily for patients with advanced or relapsed HCC who have no curative options.
- Brand names
- ET1402L1-ARTEMIS2ET-1402L1-ARTEMIS2ET 1402L1-ARTEMIS2
- Other names
- ET1402L1-ARTEMIS2ET-1402L1-ARTEMIS2ET 1402L1-ARTEMIS2ET1402L1ET-1402L1ET 1402L1anti-AFP-ARTEMIS2anti-AFP-ARTEMIS-2anti-AFP-ARTEMIS 2AFP-CARET1402L1-CARTET-1402L1-CARTET 1402L1-CARTET140202ET-140202ET 140202
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on ET1402L1-ARTEMIS2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ET1402L1-ARTEMIS2.